Flexion Therapeutics, Inc.
FLXN
FLXN was delisted on the 18th of November, 2021.
1 hedge funds and large institutions have $0 invested in Flexion Therapeutics, Inc. in 2021 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 140 closing their positions.
99% less funds holding
Funds holding: 145 → 1 (-144)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
100% less capital invested
Capital invested by funds: $230M → $0 (-$230M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 140
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$26.2M |
| 2 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
-$21.9M |
| 3 |
O
OrbiMed
New York
|
-$16.9M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$15.8M |
| 5 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$12.7M |
FLXN Hedge Fund Activity: Q4 2021 in Review
1 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in Flexion Therapeutics, Inc. (FLXN) for Q4 2021, worth a combined $0 — down 100% from $230M a quarter earlier.
Sellers outnumbered buyers: 140 funds closed out of FLXN and 0 opened new positions — a net loss of 140 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was BlackRock, exiting entirely with an estimated $26.2M sold.
- 1 institutional investor held Flexion Therapeutics, Inc. (FLXN) as of Q4 2021, down from 145 in Q3 2021.
- Funds reported $0 of Flexion Therapeutics, Inc. stock for Q4 2021, down 100% quarter-over-quarter.
- 0 funds opened new Flexion Therapeutics, Inc. positions in Q4 2021 and 140 closed out, a net change of -140 holders.
- The largest Flexion Therapeutics, Inc. seller in Q4 2021 was BlackRock, an estimated $26.2M sold.
Based on aggregated 13F filings for Q4 2021.